While pharmacotherapy for arterial thrombosis relies heavily on rapid thrombolysis with agents like recombinant tissue plasminogen activator (tPA), these treatments carry a significant risk of bleeding (5). This evidence concerns the gene PLAT and Venous thrombosis.